Lacie Emerine, APRN
Family · Columbus, OHNPI 1487151833
Payments from drug & device makers
Across 15 payments — averaging $43.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$405
- Medtronic$83
- Boston Scientific$38
- Sumitomo Pharma America, Inc.$31
- Dendreon Pharmaceuticals LLC$24
- Pfizer$21
- plus $48 from 3 others
What the payments were for
- Speaking & faculty fees$315%
- Food & beverage$24137%
- Education$37858%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 7 | $405 |
| Medtronic | 1 | $83 |
| Boston Scientific | 1 | $38 |
| Sumitomo Pharma America, Inc. | 1 | $31 |
| Dendreon Pharmaceuticals LLC | 1 | $24 |
| Pfizer | 1 | $21 |
| Tolmar, Inc. | 1 | $20 |
| Coloplast | 1 | $15 |
| 180 Medical, Inc. | 1 | $13 |
How this compares
$649 in reported general payments places this provider in the 60th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 88 | $80,871 |
| GemtesaVibegron | 89 | $76,277 |
| Tamsulosin Hcl | 254 | $4,400 |
| Trospium Chloride ErTrospium Chloride | 11 | $3,822 |
| Trospium Chloride | 27 | $2,782 |
| Finasteride | 126 | $1,358 |
| Oxybutynin Chloride ErOxybutynin Chloride | 54 | $1,271 |
| Solifenacin Succinate | 25 | $807 |
| Methenamine Hippurate | 11 | $705 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 35 | $602 |
| Cephalexin | 32 | $237 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 22 | $214 |
| Ciprofloxacin Hcl | 12 | $84 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $70 |
| Anastrozole | 22 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $405 | $80,87188 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $31 | $76,27789 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,812 family providers in Ohio.
Other family in Columbus
- Christina GastColumbus$66K
- Beth LoessinColumbus$34K
- Mary HurleyColumbus$15K
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.